Sequenom Introduces the MassARRAY Analyzer 4 System
Product News Apr 21, 2010
Sequenom, Inc. has announced the launch of its next-generation mass spectrometry system - the MassARRAY® Analyzer 4. This new high performance nucleic acid analysis platform has been designed to meet customer demand for a bench top instrument with flexibility across multiple applications.
With the capability for quantitative gene expression analysis, epigenetic nucleic acid methylation analysis as well as high-throughput genotyping and SNP fine mapping applications, the MassARRAY Analyzer 4 is designed to empower the basic and translational research community to advance findings from basic genetic and biomarker studies toward clinical utility in diagnosis, prognosis and monitoring of diseases.
The MassARRAY Analyzer 4 system will initially be offered to research-use-only (RUO) laboratories, and subject to FDA clearance will be released to CLIA-certified laboratories for the generation and implementation of laboratory-developed tests.
The new system has been configured to provide increased throughput, faster time-to-results, and the ability to cost-effectively run from tens to thousands of samples daily - making this an ideal genetic analysis system for use in basic and translational research.
Benefits of the MassARRAY Analyzer 4 system include:
• Shorter time-to-result with up to two times faster chip scan rate
• Features that accommodate the needs of both low- and high-throughput laboratories with 96 and 384-well options
• New Analyzer control software reduces hands-on time
• Flexibility to analyze any combination of genetic markers and samples
• Suitability for a variety of applications including genotyping, somatic mutations, and DNA methylation
• Improved reliability that should result in less maintenance
"With the addition of the MassARRAY Analyzer 4 system, Sequenom now offers a faster, more robust instrument which builds upon our proven MassARRAY technology shown to produce high quality data," said Michael Monko, senior vice president, genetic analysis sales and marketing. "The launch of this cost-effective instrument should allow a wider range of labs and institutions to add the power of mass spectrometry-based applications to their research and translational medicine studies. Additionally, having a system built under design control will allow us to pursue our ultimate goal of registering the system and related tests for FDA approval."